TwitterLinkedin

Contact Us

  • News & Events
    • News
    • Webinars
    • Events
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Working at PharmaLex
    • Your Application Process
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Our Milestones
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Development Strategy and Gap Analysis
            • Integrated Product Development
            • Market Access
            • Non-clinical Development Concept
              and Study Design
            • Scientific Advice
            • Scientific Due Diligence
            • Statistical Services
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Orphan Drug Designation
            • Pediatric Investigation Plan (PIP)
            • Scientific Advice
            • Statistical Services
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • IMP Management
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
            • Vendor Management and Oversight
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistical Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Environmental Risk Assessment
            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • Audit and CAPA Management
            • EU QPPV / National QPPV
            • ICSR Management
            • Literature Screening
            • Pharmacovigilance Systems
            • Safety Writing (PSUR, RMP)
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • Good Distribution Practice (GDP) Compliance
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Vendor Audit
            • Vendor Management and Oversight
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
            • Medical Information
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • Consulting
            • Consumer Healthcare
            • Generics
            • Herbal Medicines
            • Medicinal Products
            • MedTech Services
            • Pharmaceutical
            • Veterinary Drugs
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • Brexit
            • COVID-19 Support
            • Drug Re-purposing / Value-added Medicines
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Statistical Services
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • News
    • Webinars
    • Events
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Working at PharmaLex
    • Your Application Process
    • Career Opportunities
  • Training
Home > Our Services > Health Authority / Agency Interaction

Health Authority / Agency Interaction

Ensuring regulatory success

Meetings with Health Authorities such as the FDA in the US, the EMA in Europe or other major Health Authorities worldwide have shown to increase the probability of market approval and can have a most favorable impact on development times and costs. Since Health Authorities make the final decision to approve or reject products, it is highly recommended to optimize authority communication and to hold face-to-face and teleconference meetings all along the development pathway. But how do you get the best out of your meeting with a Health Authority?

Authorities encourage to start discussions as early in the development process as possible so that developers can become aware of risks and weaknesses of their development plans to address them in a timely fashion. Meetings at critical milestones during development have been shown to dramatically increase the probability of timely approval.

PharmaLex has long-standing and extensive experience of interacting with the scientific committees and working parties of the EMA (e.g. CHMP, PRAC, COMP, PDCO, CAT) and with national Health Authorities. We frequently support our clients in Scientific Advice procedures at a national or central level, and in numerous health authority interactions throughout a product’s lifecycle (e.g. requests for PRIME eligibility, Orphan Medicinal Product designations, Pediatric Investigational Plans, Marketing Authorization Applications).

In the US, PharmaLex frequently engages with the FDA and has managed numerous of meetings with different FDA divisions for our clients (e.g. for pre-IND, End of Phase 2, pre-NDA or Type C meetings) or interacted with them in other drug development and authorization related procedures.

Similarly, PharmaLex supports interactions with other major Health Authorities worldwide, facilitated by our local country-based affiliates and partners who can provide local procedural guidance and logistical support.

Want to find out more?

PharmaLex. Confidence beyond compliance.

Contact us for more information

FDA and Health Canada

As part of its regulatory service offering, PharmaLex has had extensive experience representing clients at FDA regulatory meetings and regulatory advice communications. We have worked with clients across all stages of development, from discussing IND readiness at pre-IND meetings, clarifying critical developmental questions at Type C meetings, and have assisted clients with halted development programs at Type A meetings as well as supporting later stage development at End of Phase 2 and pre-NDA meetings. PharmaLex has also assisted clients at Biosimilar Biological Product Development (BPD) meetings from Biosimilar initial advisory meeting (BIA) to BDP Type 1-4) to support biosimilar product development in the US.

PharmaLex’s expertise is not limited to specific divisions or indications, as we have interacted with nearly every division at the FDA, including specialized units such as the Division of Clinical Outcome Assessment (DCOA, formerly SEALD) and office of orphan product development (OOPD).

PharmaLex offers support during all aspects of the meeting process, from assisting with meeting strategy, through authorship, review, and submission of meeting related documents, Sponsor meeting preparation, FDA meeting attendance, and follow up activities. PharmaLex prides itself in understanding the goals of the client and identifying appropriate strategies for both effectively communicating with the FDA and fostering a collaborative relationship with the Agency, thereby resulting in efficient product development often saving Sponsors time and money.

  • Proven track record
    • Just in the last 5 years (2015-2020) supported 60+ FDA meetings, including pre-IND, End of Phase 1 and 2, Pre-NDA, Type C, Type A, and Biosimilar (BIA, BPD 1, 2 and 3) Meetings, ANDA controlled correspondence and Pre-ANDA meetings.
  • Diverse experience portfolio
    • Experience spans small and large (polymers) molecules, biologics including cell and gene therapies including regenerative medicine, recombinant proteins, biosimilars, and combination products
    • Expertise working with multiple FDA review divisions across both CDER and CBER, supporting numerous indications at various stages of development
    • Expertise in various therapeutic areas such as rare diseases, advanced therapies, acute and chronic pain, CNS disease, oncology, and gastrointestinal disorders providing a wide range of experience to support multiple different types of programs
  • Ability to support all aspects of meeting preparation and related activities
    • Substantial experience in assisting clients with FDA meeting strategy, formulating thoughtful meeting discussion topics, designed to maximize meeting opportunity, leading to efficient development programs
    • Significant experience with authorship and submission of required meeting materials, including meeting requests and briefing documents, in compliance to FDA guidelines, to ensure FDA is well informed of the Sponsor’s program and developmental strategy to support meeting discussion
    • Able to prepare and lead meeting rehearsals to certify all attendees are well prepared prior to meeting with the Agency, including assisting with overall messaging strategy to support the Sponsor’s goals of the meeting
    • Ability to attend and/or lead FDA meetings on behalf of the Sponsor, assisting with the facilitation of the meeting discussion and fostering collaboration with the FDA

Aiding and steering of follow-up activities and interactions occurring from the FDA meeting including authorship and submission of meeting minutes and developing appropriate program strategy based on FDA meeting discussion.

Europe – EMA & national Health Authorities

Meetings with Health Authorities are highly valuable opportunities to consolidate and optimize your development strategy with the input of the future decision makers on your marketing authorization application. Opportunities for direct interactions with regulators are still limited though nowadays all major authorities offer regulatory and scientific advice meetings. To get the best out of them, they must be well prepared.

PharmaLex has extensive experience of leading clients through the Scientific Advice process. We frequently support centralized Scientific Advice process at the SAWP/CHMP or national Health Authorities. In addition, we support our clients interacting with all scientific committees and working parties of the EMA (e.g. CHMP, PRAC, COMP, PDCO, CAT).

We make you aware what Health Authorities pay attention to, what kind of inquiries they make and what they expect to hear from applicants.

  • Proven track record (last five years)
    • > 75   Scientific Advices
    • > 25   Pediatric Investigational Plans (PIP)
    • > 15   Orphan Medicinal Product (OMP) designations
      5   Advanced Therapy Medicinal Product (ATMP) classifications
      5   PRIME eligibility and Innovation Task Force (ITF) meetings
      3   Adaptive Pathway eligibility applications
    • > 10   CP Pre-Submission and Rapporteur meetings
  • Supporting all aspects of meeting preparation
    • Advice: We help to decide on the strategy of approaching regulatory health authorities and which questions to ask.
    • Documentation: We provide support to compile a briefing package including all necessary documentation.
    • Coaching: We train your meeting delegates to ask the right questions and to obtain relevant answers.
    • Meeting: We attend and/or lead the meeting with the Health Authority on behalf of the client facilitating the meeting discussion.
    • Response: We use our regulatory expertise and experience to interpret health authority requests and recommendations.
    • Implementation: We support project teams to adequately and timely address the advice received.

Related News

First approved application for BioBag® medicinal larvae for Biomonde GmbH
25th August 2020
pharmalex Clinical trials - web
Clinical trials in the post Brexit Europe
24th August 2020
Tablets drugs pharma
Global collaboration key as COVID-19 ramps up the pressure
5th August 2020

Related Resources

Thought Leadership

  • Improving the chances of EU approval
  • The Evolving Influence of the FDA on Pharma

Fact Flyers

  • FDA meetings and health authority interactions

Case Studies

  • Pre-IND Meeting
  • End of Phase-2 meeting
  • Type C Meeting
  • Dendritic cell vaccine (oncology)
  • MA applications to EMA and FDA in parallel
  • Local lifecycle Regulatory Affairs management
  • Multi-country Phase III clinical trial support

White Papers

  • Pre-IND meetings | The opportunity for early FDA feedback

Webinars

  • Learn how to get the most out of FDA meetings

Infographics

  • A Guide to FDA Meetings

Related Services

  • ANDA Withdrawals
  • Digital Health Questionnaire
  • Healthcare Compliance and Medical Approval
  • MAA / NDA Submissions
  • SMARTDECISIONS
  • SMARTMDR
  • Tobacco and Vape Products

What our clients say

Able to explain technical details so non-experts can understand

US based small / virtual company
Partner

We really appreciate your responsiveness and availability during our previous exchanges and it is what we are waiting for from our partner.

Small Medium Sized Company, UK
Head of Regulatory Affairs
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
Tweets by @PharmaLexGLOBAL
COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Worked with us and our contractors to help us achieve our tight targets, operate with our systems and procedures and are considered invaluable part of our team

    US based large development group
    VP Regulatory / Quality
PharmaLex
©2021 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit Logo

#AskTheExpert #TogetherBEYONDCOVID19





    Select your state:

    .
    You can unsubscribe at any time at data.protection@pharmalex.com

    If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

    #TogetherBEYONDCOVID19

    We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for

      Please DO NOT send us event/conference information.
      We will not respond and these will be deleted immediately.





      Select your state:

      .
      You can unsubscribe at any time at
      data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      Privacy Policy

      This can be specific information about signing up to the newsletter.

      Pellentesque lobortis, tellus at ultrices ullamcorper, lectus tellus consectetur lectus, id consequat leo quam quis eros. Mauris pellentesque tortor a augue pellentesque ultricies. Phasellus sit amet suscipit orci, vel dapibus ligula. Maecenas at pellentesque lectus, sit amet tristique felis. Integer fringilla risus ac neque mollis, at imperdiet lacus sodales. In vehicula orci sed vulputate interdum. Nunc sagittis non nunc eget sollicitudin.

      Maecenas a mattis erat. Phasellus cursus erat non nisl pulvinar ultricies. Aenean id fringilla libero. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Morbi in ultrices elit. Suspendisse egestas hendrerit est. Integer pellentesque nisl ut justo tempus, nec suscipit dolor luctus. Cras vestibulum elementum tincidunt.

      In compliance with the Spanish Law 15/1999, of Protection of Personal Data and in accordance with regulations approved by the Spanish RD 994/1999 inform you that your data will be part of a file located in Friedrichsdorf (Germany), whose ownership belongs to Pharmalex Spain S.L.U. The purpose of these data is the insertion in a potential job selection process. Inform the user that at any time may exercise their right of access, rectification, and deletion of data through email curriculum@pharmalex.com or to this postal address Pharmalex Spain. Coso 103, 50001 Zaragoza, Spain.